<DOC>
	<DOC>NCT02118896</DOC>
	<brief_summary>The purpose of this study was to offer patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) the possibility to continue FK506E (MR4) until commercial availability of the drug and to record long term efficacy and safety data.</brief_summary>
	<brief_title>Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant</brief_title>
	<detailed_description>The objective of this study was to asses the safety and effecicacy of FK506E (MR4) as a long-term treatment in transplant recipients. Only patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) and had received at least one dose of study medication were enrolled.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients who had already participated in the previous phase II pharmacokinetic or phase III studies with FK506E (MR4). Patients capable of understanding the purpose and risks of the study, who had been fully informed and given written informed consent to participate in the study. Pregnant women or nursing mothers. Women unwilling or unable to use adequate contraception during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>FK506E</keyword>
	<keyword>MR4</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Renal Transplantation</keyword>
	<keyword>Heart Transplantation</keyword>
</DOC>